Effect of Hydrogen Inhalation Therapy on Hearing Loss of Patients With Nasopharyngeal Carcinoma After Radiotherapy.
Xiaofeng Kong, Tianyu Lu, You-Yong Lu, Zhinan Yin, Kecheng Xu · Frontiers in medicine · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 17 patients with long-term survival of nasopharyngeal carcinoma after radiotherapy, after hydrogen inhalation treatment, no adverse reactions such as nosebleed, chest pain, dyspnea, nausea, vomiting, dizziness, earache and allergic reaction were observed. These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 17 patients with long-term survival of nasopharyngeal carcinoma after radiotherapy. After hydrogen inhalation treatment, no adverse reactions such as nosebleed, chest pain, dyspnea, nausea, vomiting, dizziness, earache and allergic reaction were observed.
What the Researchers Studied
The researchers studied 17 patients with long-term survival of nasopharyngeal carcinoma after radiotherapy. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen exposure: 2 L/min total gas flow; H₂ component not established; reported treatment duration: 12 weeks. After hydrogen inhalation treatment, no adverse reactions such as nosebleed, chest pain, dyspnea, nausea, vomiting, dizziness, earache and allergic reaction were observed. The authors concluded that this is the first prospective study on the effect of hydrogen inhalation on hearing improvement in patients with deafness after radiotherapy/chemotherapy for nasopharyngeal carcinoma, suggesting that continuous hydrogen inhalation may be an alternative rehabilitation therapy for these patients. Its mechanism of action might be associated with hydrogen's functions in controlling oxidative stress and inflammation; protecting cells; and improving blood perfusion. The mechanism by which hydrogen improves hearing loss in patients with nasopharyngeal carcinoma after radiotherapy or chemoradiotherapy remains unclear.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 17 patients with long-term survival of nasopharyngeal carcinoma after radiotherapy. The reported sample size was 17. The study used a human clinical study. The source-reported hydrogen exposure was 2 L/min total gas flow; H₂ component not established. The reported treatment duration was 12 weeks.
Limitations and Safety
It is worth noting that the hydrogen inhalation is very safe. Safety evaluation was conducted once every 4 weeks after hydrogen inhalation, covering symptoms of nose bleeding, cough, chest pain, dyspnea, nausea, vomiting, dizziness, earache and allergic reaction.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.